SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Paratek Pharmaceuticals, Inc. (Nasdaq – PRTK)

BALA CYNWYD – June 6, 2023 /NewsFile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq – PRTK) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings,” and together with Gurnet Point, the “Buyers”). Under the terms of the merger agreement, the Buyers will acquire all outstanding shares of Paratek for $2.15 per share in cash, plus a CVR of $0.85 per share payable upon the achievement of $320 million in U.S. NUZYRA net sales.

The investigation concerns whether the Paratek Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether the Buyers are paying too little for the Company. For example, the deal consideration (including the CVR) is less than the 52-week high of $3.65 for the Company’s shares.

If you own shares of Paratek stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.